Cargando…

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have emerged as a novel treatment option in patients with hypercholesterolemia. Evolocumab and alirocumab have achieved consistent and significant (around 60%) reduction in low-density lipoprotein cholesterol (LDL-C) levels when added to st...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hassan, Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2015
Materias:	Lessons from the Trials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625402/ https://www.ncbi.nlm.nih.gov/pubmed/26566525 http://dx.doi.org/10.5339/gcsp.2015.20

Ejemplares similares

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum
por: Hassan, Mohamed, et al.
Publicado: (2014)

CANHEART: Is HDL cholesterol a cardiovascular specific risk factor?
por: Hassan, Mohamed, et al.
Publicado: (2016)

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A(2) (Lp-PLA(2)) as a biomarker or risk factor for cardiovascular diseases
por: Hassan, Mohamed
Publicado: (2015)

The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
por: Wagdy, Kerolos
Publicado: (2020)

Gulf CARE: Heart failure in the Middle East
por: Hassan, Mohamed
Publicado: (2015)

HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack
por: Hassan, Mohamed
Publicado: (2014)

APOC3: Triglycerides do matter
por: Hassan, Mohamed
Publicado: (2014)

Niemann-Pick C1-Like 1 protein: Another target for treatment of dyslipidemia? Evidence from the Myocardial Infarction Genetic Consortium and IMPROVE-IT trials
por: Hassan, Mohamed
Publicado: (2014)

CANTOS: A breakthrough that proves the inflammatory hypothesis of atherosclerosis
por: Hassan, Mohamed
Publicado: (2018)

Towards tailoring blood pressure control in HFpEF: Lessons from OPTIMIZE-HF
por: Hassan, Mohamed
Publicado: (2019)

NEAT HFpEF: Organic nitrates fail to deliver
por: Wagdy, Kerolos, et al.
Publicado: (2016)

ASGR1 - a new target for lowering non-HDL cholesterol
por: Hassan, Mohamed, et al.
Publicado: (2016)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

The Dallas Heart Study using the probability sample technique for ethnicity and cardiovascular health differences
por: Al Suwaidi, Jassim
Publicado: (2015)

EMMY: The continued expansion of clinical applications of SGLT2 inhibitors
por: Kotit, Susy
Publicado: (2023)

Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
por: Suwaidi, Jassim Al
Publicado: (2016)

Is there an increased cardiovascular risk in metabolically healthy obese individuals? Lessons from the HUNT (Nord-Trøndelag Health) study
por: Al Suwaidi, Jassim
Publicado: (2014)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

Long-term outcomes from the UK Biobank on the impact of coffee on cardiovascular disease, arrhythmias, and mortality: Does the future hold coffee prescriptions?
por: Susy, Kotit
Publicado: (2023)

Lessons from the first-in-human in vivo CRISPR/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy
por: Kotit, Susy
Publicado: (2023)

Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations
por: Kotit, Susy
Publicado: (2023)

FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation
por: Sayed, Mohamed, et al.
Publicado: (2016)

Culprit lesion-only versus complete revascularization in patients with STEMI: Lessons learned from PRAMI, CvLPRIT, and DANAMI-3 PRIMULTI
por: Hassan, Ahmed, et al.
Publicado: (2015)

ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation
por: ElMaghawry, Mohamed
Publicado: (2015)

REVERSE 5-year follow up: CRT impact persists
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

DECAAF: Emphasizing the importance of MRI in AF ablation
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Dronedarone-digoxin interaction in PALLAS: A foxglove connection?
por: ElMaghawry, Mohamed, et al.
Publicado: (2015)

Takotsubo cardiomyopathy: A potentially serious trap (Data from the International Takotsubo Cardiomyopathy Registry)
por: Wagdy, Kerolos, et al.
Publicado: (2015)

STOP-HF: Expanding the role of HF programs into the community
por: ElMaghawry, Mohamed, et al.
Publicado: (2014)

BLOCK-HF: CRT gains new ground
por: ElGuindy, Ahmed M., et al.
Publicado: (2013)

TASTE: One-year follow-up results
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2015)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

HEAT-PPCI: A clear and welcome win for heparin
por: ElGuindy, Ahmed M.
Publicado: (2014)

STAMPEDE: Bariatric surgery gains more evidence based support
por: Al Suwaidi, Jassim
Publicado: (2014)

TAVI: New trials and registries offer further welcome evidence – U.S. CoreValve, CHOICE, and GARY
por: Pighi, Michele, et al.
Publicado: (2014)

RE-ALIGN: First trial of novel oral anticoagulant in patients with mechanical heart valves – The search continues
por: Shazly, Ahmed, et al.
Publicado: (2014)

SYMPLICITY HTN 3: The death knell for renal denervation in hypertension?
por: Patel, Hitesh C, et al.
Publicado: (2014)

FAME 2 – The best initial strategy for patients with stable coronary artery disease: Do we have an answer at last?
por: ElGuindy, Ahmed M, et al.
Publicado: (2013)

ALDO-DHF & Paramount
por: ElGuindy, Ahmed M
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gkcgf3gml3fgtprichp2ljih3o